Bristol-Myers Squibb (BMY) said Monday that its drug Breyanzi achieved "high, lasting response rates" among patients with relapsed or refractory marginal zone lymphoma in a phase 2 study.
The company said 95.5% of 66 evaluable patients showed an overall response, while 62.1% showed a complete response.
At 24 months, 88.6% sustained a response, 85.7% achieved progression-free survival, and 90.4% showed overall survival, the company said.
Median survival for patients with marginal zone lymphoma with multiple relapses is 3 to 5 years, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。